24 results about "Traumatic brain damage" patented technology

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

The disclosure relates to compositions including STING inhibitors. Methods of treating subjects with a traumatic brain injury by administering STING inhibitors are also included.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

Provided are systems, methods, and devices for providing mediation of a traumatic brain injury. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with a traumatic brain injury. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the traumatic brain injury. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

The application discloses a carrier for engineering miR-124-3p The application discloses an application of an exosome hydrogel in preparation of a drug for treating traumatic brain injury, and belongs to the technical field of biological carrier drug delivery. miR-124- 3p The exosome vesicle structure can improve the stability of the miRNA in the body and the delivery efficiency of the miRNA into nerve cells, thereby enhancing the bioavailability. The engineering exosome is embedded in the QCC / OHM hydrogel system, so that the engineering exosome forms a stable delivery platform at the injury site, realizes sustained release and local enrichment of the exosome. The hydrogel material has good tissue adaptability, can enter irregular brain injury interstitial spaces through minimally invasive injection and form a scaffold structure, and provides a favorable microenvironment for nerve repair. The application can overcome the problems of poor stability of treatment molecules, short local retention time and difficulty in realizing multi-mechanism synergistic treatment, and provides a new technical scheme for treatment of traumatic brain injury.

A method, a structure, and a computer system for traumatic event detection. The exemplary embodiments may include collecting data using sensors worn by a user and identifying a traumatic event based on applying a model to the data, wherein the model correlates values of the data with traumatic events and traumatic brain injuries. The exemplary embodiments may further include identifying the traumatic brain injury resulting from the traumatic event.

The invention relates to the technical field of biological medicine and polymer targeted delivery, and provides an oligodendrocyte-derived exosome and application thereof in preparation of a medicine for treating traumatic brain injury. Comprising the following steps: separating and culturing primary oligodendroglia cells from brain tissues; placing the maturely cultured oligodendroglia cells in a sugar-free and serum-free culture medium, performing oxygen-glucose deprivation treatment in an anoxic environment, then continuously culturing in a normal sugar-containing culture medium under a normal oxygen condition, and collecting cell culture supernate; and separating the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment from the supernate by adopting a gradient ultracentrifugation method to obtain the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment. The exosome derived from the oligodendroglia is applied to preparation of the medicine for treating the traumatic brain injury and has the advantages of being high in targeting performance and good in penetrability, that is, the exosome is used as a natural carrier, the defect that a traditional traumatic brain injury medicine is difficult to penetrate through a blood brain barrier is perfectly overcome, and the exosome can efficiently enter brain tissue and be taken by microglia.

Here disclosed is a set of biomarkers useful for diagnosis, prognosis, treatment, determining the short- and long-term effects of traumatic brain injury (TBI) in a subject. Methods for using the biomarkers also are described.

The present invention provides compounds, compositions and methods for prophylaxis and treatment of traumatic brain injury using a P13 peptide or P13 fusion peptide which can be administered prior to or after traumatic brain injury and which can ameliorate the biophysiological indicators of brain injury and improve neurological outcomes in subjects suffering from traumatic brain injury.

The invention discloses a traumatic brain injury patient intracranial pressure continuous prediction method based on an LSTM model, and belongs to the technical field of medical monitoring. Comprising the steps that intracranial pressure data of a patient are collected in real time through an invasive intracranial pressure monitor, and the sampling rate is 100 Hz; the collected data are preprocessed, the reasonable range is set to be-5 mmHg to 50 mmHg, sliding window smoothing processing and abnormal value detection are adopted, and normalization processing is carried out; training an LSTM (Long Short Term Memory) model by using the preprocessed data, wherein an initial training set is data of each patient in the first 30 minutes; the trained LSTM model is used for outputting an intracranial pressure predicted value in the next 10 minutes every 10 minutes; high and low intracranial pressure events are classified on the basis of the predicted values, and when no less than 6 predicted values in the 10 predicted values exceed 20 mmHg, the high intracranial pressure events are judged; and updating the LSTM model according to newly acquired data to realize adaptive optimization. The method is suitable for real-time monitoring of traumatic brain injury patients, provides the dynamic trend of the intracranial pressure through continuous prediction, and provides support for clinical decision making.

Methods and devices related to blast and environmental exposure monitoring, introducing a risk-based model for system deployment, and at its highest level, performing head-based blast vectoring within the system for monitoring the exposure and post-event surveillance, including biometric data acquisition, and probing behavioral indicators to perform device driven traumatic brain injury risk assessment.

A system to rehabilitate stroke or traumatic brain injury survivors includes a brain machine interface that receives brain signals from the brain of a patient. The brain signals represent motor intent of the patient with respect to a hand of the patient that has impaired dexterous hand function due to neurological injury. A limb interface mounts to the hand of the patient. The limb interface detects feedback in the hand that results from the brain signals and helps to control the hand in accordance with the motor intent of the brain signals. The system also includes a processor operatively coupled to the brain machine interface and the limb interface. The processor is configured to synchronize the motor intent with the feedback to increase plasticity between sensory and motor areas of the brain to improve voluntary control of the hand, including dexterous hand functions such as multiple types of grasp.

Method and systems for translating biological signals to perform various operations associated with a computing device is provided. The method can include accessing biological-signal data that was collected by a biological-signal data acquisition assembly that comprises a housing having one or more clusters of electrodes. Each cluster of the one or more clusters of electrodes can include at least an active electrode. The method can also include identifying, based on the biological-signal data, a first signal that represents a first intent to move a first portion of a body of the subject. The first signal is generated before a second signal, in which the second signal represents a second intent to move a second portion of the body of the subject. The method can also include translating the first signal to identify a first operation to be performed by a computing device.

A polypeptide compound, or a variant thereof, or a pharmaceutically acceptable salt thereof, useful in the preparation of a medicament for the treatment of traumatic brain injury.

Methods and systems for assessing brain health of a patient are described. In certain forms, the assessment of the presence of traumatic brain injury (TBI), such as mild traumatic brain injury (mTBI), of the patient is performed by analyzing data representative of movement of the patient's eye.

Provided are systems, methods, and devices for providing mediation of a traumatic brain injury. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with a traumatic brain injury. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the traumatic brain injury. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

Presented herein are compositions and methods involving mitochondrial organelle transplantation for use in the treatment of traumatic brain injury (TBI), e.g., mild traumatic brain injury (mTBI), in a subject. compositions and methods for treatment of traumatic brain injury (tbi), for example, mild traumatic brain injury (mtbi)

The present disclosure provides a composition comprising an active ingredient that is encapsulated in suspension of particles comprising a biodegradable polymer containing an effective amount of the active ingredient, wherein the particles are configured to bypass the blood brain barrier, wherein the nutraceutical agent is synthetic D-beta hydroxybutyrate, and wherein targeted delivery is to the brain. It further provides a method for promoting healing of the brain after a traumatic brain injury comprising neuroinflammation and a method for promoting brain health. It further provides a pharmaceutical composition for use in reducing risk of brain damage due to an acquired brain injury in a subject susceptible to, or otherwise at risk of, the acquired brain injury, said composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is a synthetic D-beta-hydroxybutyrate, wherein the treatment comprises targeted delivery to the olfactory region of the nasal cavity of the subject by administering the composition intranasally (a) before the subject participates in an event where an acquired brain injury is a known risk; (b) after the subject participates in the event for use in treating symptoms of the acquired brain injury of the subject comprising neuroinflammation; or both, wherein the treatment is neuroprotective.

A system for monitoring if a person has been exposed to a shock wave, pressure wave, or the like, which has a magnitude great enough to cause, or potentially cause injury, such as traumatic brain injury. The system may utilize a rupture disc which is formed so as to rupture upon exposure to pressure waves known to cause injury.

Methods and systems for investigating the brain health of patients are described. In certain forms, the presence of traumatic brain injury (TBI), such as mild traumatic brain injury (mTBI), is investigated in patients by analyzing data representing the patient's eye movements.

CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.

Compositions and methods for diagnosis and treatment of increased risk for mild traumatic brain injury are disclosed.

The present disclosure relates to pegylated steroid derivatives (e.g., progesterone derivatives) which may be useful in methods of treatment of the human or animal body. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use in the treatment of disorders, such as managing inflammation (e.g., inflammation resulting from traumatic brain injury or stroke).